Aaron Gal Recent News
Regeneron Is 'One Of The Stronger Growers In Biotech'
Biogen Optionality Looking Attractive; Bernstein Initiates At Outperform
Stiff Biosimilar Headwinds To Negatively Impact Amgen's Aging Drug Portfolio
Bernstein Lists Active Buyers Of Ophthalmology Companies
Theravance Just Lost Its Catalyst
Analysts See Allergan Bid Of Over $180, Possibility of 'Hostile' Bid
UPDATE: Bernstein Research Reiterates on Momenta Pharmaceuticals Following 3Q13 Results Report